Dr. Hönle AG revised earnings guidance for the year 2022/2023. For the year 2022/2023, the company expects sales of EUR 100 million to EUR 105 million for the company in the 2022/2023 financial year. Until now, it had assumed that sales would be lower than in the previous year (EUR 126.5 million).

Furthermore, it expects an operating result (EBIT) without non-recurring effects of EUR 5.5 million to EUR 6.5 million as well as negative non-recurring effects of EUR 13.5 million, which are mainly related to the shutdown of the mobile air disinfection systems product line. Overall, it assumes an operating result (EBIT) negative of EUR 7 million to EUR 8 million. Until now, the Management Board had assumed that the operating result (EBIT) would be significantly higher than the adjusted operating result of the previous year (EUR 8.9 million).